Company intelligence / Profile preview

A28 Therapeutics

Louisiana, United Statesa28therapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

AT‑101, the company’s lead compound, has completed a Phase 2a study showing an attractive safety profile and promising anti-tumor activity. The agent can be used alone or in combination with immuno-oncology drugs and chemotherapy. It targets cancers overexpressing the LHRH receptor, including top ten solid tumors by prevalence. The company plans further clinical studies in metastatic ovarian cancer with liver metastases and hepatocellular carcinoma.

Therapeutic areas: Oncology
Modalities: Targeted lytic peptides
Industry: Biotech

Drug pipeline

4 assets

CA028

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

GATC Health — partnership announced January 2025 to leverage AI-driven drug discovery capabilities.

Beyond the preview

Go deeper on A28 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A28 Therapeutics.

Explore the full profile